NASDAQ:UPB Upstream Bio (UPB) Stock Price, News & Analysis $15.13 +1.16 (+8.30%) As of 02:10 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Upstream Bio Stock (NASDAQ:UPB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Upstream Bio alerts:Sign Up Key Stats Today's Range$13.99▼$15.2550-Day Range$8.93▼$14.3452-Week Range$5.14▼$29.46Volume509,415 shsAverage Volume338,678 shsMarket Capitalization$813.90 millionP/E RatioN/ADividend YieldN/APrice Target$56.50Consensus RatingBuy Company Overview Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts. Read More Upstream Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreUPB MarketRank™: Upstream Bio scored higher than 41% of companies evaluated by MarketBeat, and ranked 735th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingUpstream Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageUpstream Bio has received no research coverage in the past 90 days.Read more about Upstream Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Upstream Bio are expected to grow in the coming year, from ($4.30) to ($2.37) per share.Price to Book Value per Share RatioUpstream Bio has a P/B Ratio of 1.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Upstream Bio's valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for UPB. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldUpstream Bio does not currently pay a dividend.Dividend GrowthUpstream Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for UPB. News and Social Media2.5 / 5News Sentiment0.53 News SentimentUpstream Bio has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.04 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Upstream Bio this week, compared to 2 articles on an average week.Search Interest1 people have searched for UPB on MarketBeat in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Upstream Bio insiders have not sold or bought any company stock.Percentage Held by Insiders13.56% of the stock of Upstream Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Upstream Bio's insider trading history. Receive UPB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Upstream Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address UPB Stock News HeadlinesPromising Outlook for Upstream Bio, Inc. as Verekitug Advances in Inflammatory ConditionsJuly 28 at 6:58 AM | tipranks.comPositive Outlook for Upstream Bio, Inc. Driven by Promising Phase II Study of Verekitug in CRSwNP TreatmentJuly 28 at 6:58 AM | tipranks.comTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.July 30 at 2:00 AM | Porter & Company (Ad)Upstream Bio Inc. (UPB) Stock Price Today - WSJJuly 25, 2025 | wsj.comUpstream Bio begins phase 2 COPD trial for verekitugJuly 10, 2025 | uk.investing.comUpstream Bio Initiates Phase 2 VENTURE Trial for Verekitug in Moderate-to-Severe COPD, Expanding Its Respiratory PortfolioJuly 8, 2025 | quiverquant.comQUpstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)July 8, 2025 | globenewswire.comUPB Upstream Bio, Inc. - Seeking AlphaJune 28, 2025 | seekingalpha.comSee More Headlines UPB Stock Analysis - Frequently Asked Questions How have UPB shares performed this year? Upstream Bio's stock was trading at $16.44 at the beginning of the year. Since then, UPB shares have decreased by 9.5% and is now trading at $14.8780. How were Upstream Bio's earnings last quarter? Upstream Bio, Inc. (NASDAQ:UPB) issued its quarterly earnings data on Tuesday, May, 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by $0.02. The company earned $0.57 million during the quarter, compared to analysts' expectations of $0.71 million. When did Upstream Bio IPO? Upstream Bio (UPB) raised $200 million in an IPO on Friday, October 11th 2024. The company issued 12,500,000 shares at $15.00-$17.00 per share. JPMorgan, TD Cowen, Piper Sandler and William Blair acted as the underwriters for the IPO. Who are Upstream Bio's major shareholders? Top institutional shareholders of Upstream Bio include CWM LLC (0.01%). Insiders that own company stock include Erez Chimovits and Ai Upstream Llc. View institutional ownership trends. How do I buy shares of Upstream Bio? Shares of UPB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/06/2025Today7/30/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:UPB Previous SymbolNASDAQ:UPB CIK2022626 Webupstreambio.com Phone(781) 208-2466FaxN/AEmployees38Year FoundedN/APrice Target and Rating Average Price Target for Upstream Bio$56.50 High Price Target$75.00 Low Price Target$38.00 Potential Upside/Downside+279.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio47.43 Quick Ratio47.43 Sales & Book Value Annual Sales$2.30 million Price / Sales348.58 Cash FlowN/A Price / Cash FlowN/A Book Value$8.77 per share Price / Book1.70Miscellaneous Outstanding Shares53,794,000Free Float46,500,000Market Cap$800.35 million OptionableN/A BetaN/A 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (NASDAQ:UPB) was last updated on 7/30/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredDrone Company Secures Major Defense Contract Amid Sweeping Policy ShiftOn July 10th, the White House and DoD announced a sweeping new directive to fast-track U.S. drone dominance. ...The Tomorrow Investor | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredNvidia’s next AI move could catch traders flat-footedTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredOne stock to replace Nvidia"I said 'SELL' before this stock dropped 90%. Today, I'm shouting 'BUY NOW' before it's too late." In 2000,...InvestorPlace | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thNew China tariffs hit August 12th—and Wall Street’s already moving. Banks and billionaires are quietly shif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Upstream Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Upstream Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.